NCT06165536 Laryngeal and Vocal Tract Strategies to Reduce Vocal Fold Contact Pressure
| NCT ID | NCT06165536 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Los Angeles |
| Condition | Mid-membranous Vocal Fold Lesion |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2028-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-12-01 with a primary completion date of 2028-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phonotraumatic vocal hyperfunction is one of the most frequently occurring conditions to affect the voice. This voice disorder often involves vocal fold injury due to repeated, excessive contact pressure between the vocal folds when they collide during voice production. In the clinic, voice therapy attempts to modify unhealthy vocal behaviors through different techniques or exercises. While voice therapy is generally considered effective, the scientific rationale for its therapeutic benefits still remains unclear. It is generally believed that these exercises lead to adjustments in the larynx and vocal tract that reduce vocal fold contact pressure. However, this assumption has never been tested in humans or laboratory experiments. The goal of this clinical trial is to investigate the effectiveness of voice therapy in reducing vocal fold contact pressures and in eliciting the hypothesized favorable laryngeal and vocal tract configurations.
Eligibility Criteria
Inclusion Criteria: * Ages 18-40 years (to minimize developmental changes associated with adolescent and elderly age) * Clinic diagnosis by a fellowship trained laryngologist of mid-membranous lesions that by history and appearance are phonotraumatic * Must be referred for voice therapy Exclusion Criteria: * Medical comorbidities (e.g., autoimmune disorders) beyond seasonal allergy and laryngopharyngeal reflux * Vocal fold lesions generally regarded to be less responsive to voice therapy (e.g. vocal fold cysts). * Claustrophobia * Inability to replicate fundamental frequencies required for the study at the intensity levels determined
Contact & Investigator
Zhaoyan Zhang
PRINCIPAL INVESTIGATOR
University of California, Los Angeles
Frequently Asked Questions
Who can join the NCT06165536 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Mid-membranous Vocal Fold Lesion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06165536 currently recruiting?
Yes, NCT06165536 is actively recruiting participants. Contact the research team at zyzhang@ucla.edu for enrollment information.
Where is the NCT06165536 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06165536 clinical trial?
NCT06165536 is sponsored by University of California, Los Angeles. The principal investigator is Zhaoyan Zhang at University of California, Los Angeles. The trial plans to enroll 60 participants.